Cellular and molecular mechanisms responsible for progression of Barrett's metaplasia to esophageal carcinoma

Gastroenterology Clinics of North America

Volumn 31, Issue 2, 2002, Pages 461-479

  Beilstein, Michelle ^a   Silberg, Debra ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CATENIN; CELL ANTIGEN; CYTOCHROME P450; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; ONCOPROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P16; PROTEIN P53; UVOMORULIN;

APOPTOSIS; BARRETT ESOPHAGUS; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CHROMOSOME ABERRATION; COLON POLYPOSIS; ESOPHAGUS CARCINOMA; HUMAN; METAPLASIA; ONCOGENE C MYC; ONCOGENE RAS; PLOIDY; REVIEW; ADENOCARCINOMA; CELL DIVISION; CELL TRANSFORMATION; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PRECANCER;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN; METAPLASIA; PRECANCEROUS CONDITIONS; HUMANS;

EID: 0036314064     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8553(02)00013-4     Document Type: Review

References (118)

1. Prevalence of metaplasia at the gastro-oesophageal junction
2. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease
3. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction
4. Barrett's oesophagus
5. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: Report on the Cleveland Clinic Barrett's Esophagus Registry
6. Adenocarcinoma and Barrett's esophagus. An overrated risk?
7. Barrett's esophagus: The metaplasia-dysplasia-carcinoma sequence: Morphological aspects
8. Predictors of progression to cancer in Barrett's esophagus: Baseline histology and flow cytometry identify low- and high-risk patient subsets
9. Expression of p53, PCNA, and C-erbB-2 in Barrett's metaplasia and adenocarcinoma
10. Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: Subdivision of S phase
11. Apoptotic and proliferative activity in the neoplastic progression of Barrett's oesophagus: A comparative study
12. Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus
13. Role of apoptosis in modulation of the growth of human colorectal tubular and villous adenomas
14. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression
15. Cancer cell cycles
16. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue
17. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
18. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16
19. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus
20. Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma
21. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus
22. Induction of c-fos and c-myc proto-oncogene expression by epidermal growth factor and transforming growth factor alpha is calcium-independent
23. Proliferating cell nuclear antigen in oesophageal diseases; Correlation with transforming growth factor alpha expression
24. Association of transforming growth factor alpha (TGFA) and its precursors with malignant change in Barrett's epithelium: Biological and clinical variables
25. Acidic fibroblast growth factor is progressively increased in the development of oesophageal glandular dysplasia and adenocarcinoma
26. Do angiogenesis and growth factor expression predict prognosis of esophageal cancer?
27. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways
28. Her-2/neu gene amplification, elevated mRNA expression, and protein overexpression in the metaplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus
29. Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus
30. HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma
31. Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: Pathological and prognostic correlations
32. Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas
33. c-erbB-2 over-expression in the dysplasia/carcinoma sequence of Barrett's oesophagus
34. The Rb/E2F pathway and cancer
35. Frequent loss of heterozygosity at the retinoblastoma locus in human esophageal cancers
36. Expression of the RB protein, allelic imbalance of the RB gene and amplification of the CDK4 gene in metaplasias, dysplasias and carcinomas in Barrett's oesophagus
37. Significance of Fas and retinoblastoma protein expression during the progression of Barrett's metaplasia to adenocarcinoma
38. The genetic basis of colorectal cancer: Insights into critical pathways of tumorigenesis
39. Allelic loss involving the tumor suppressor genes APC and MCC and expression of the APC protein in the development of dysplasia and carcinoma in Barrett esophagus
40. LOH at the sites of the DCC, APC, and TP53 tumor suppressor genes occurs in Barrett's metaplasia and dysplasia adjacent to adenocarcinoma of the esophagus
41. Barrett's esophagus: Metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursors to invasive adenocarcinoma
42. Reduced expression of the cadherin-catenin complex in oesophageal adenocarcinoma correlates with poor prognosis
43. Cell binding function of E-cadherin is regulated by the cytoplasmic domain
44. Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: Correlation with disease progression and dedifferentiation
45. Abnormal expression of the E-cadherin-catenin complex in dysplastic Barrett's oesophagus
46. Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas
47. Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus
48. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
49. Aspirin, NSAIDS, and colon cancer prevention: Mechanisms?
50. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer
51. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
52. Cyclooxygenase-2 expression in Barrett's esophagus
53. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence
54. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure
55. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas
56. Inhibition of angiogenesis by nonsteroidal antiinflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing
57. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells
58. The Fas death factor
59. Overexpression of Fas ligand (FasL) during malignant transformation in the large bowel and in Barrett's metaplasia of the esophagus
60. Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma
61. Decreased expression of Fas (CD95/APO1) associated with goblet cell metaplasia in Barrett's esophagus
62. Mutations in apoptosis genes: A pathogenetic factor for human disease
63. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
64. Apoptosis is inhibited early in the dysplasia-carcinoma sequence of Barrett esophagus
65. Analysis of Ki-67, p53 and Bcl-2 expression in the dysplasia-carcinoma sequence of Barrett's esophagus
66. Barrett's esophagus, apoptosis and cell cycle regulation: Correlation of p53 with Bax, Bcl-2 and p21 protein expression
67. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
68. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus
69. Participation of p53 protein in the cellular response to DNA damage
70. p53 and neoplastic progression in Barrett's esophagus
71. Gain-of-function mutations in the tumor suppressor gene p53
72. p53-mutant clones and field effects in Barrett's esophagus
73. Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell sorting, whole genome amplification and microsatellite polymorphisms
74. 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy
75. Genetic analysis of long-term Barrett's esophagus epithelial cultures exhibiting cytogenetic and ploidy abnormalities
76. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus
77. Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus
78. Flow cytometric DNA analysis and p53 protein expression show a good correlation with histologic findings in patients with Barrett's esophagus
79. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: Immunohistochemical marker predictive of progression
80. p53 protein accumulation is a specific marker of malignant potential in Barrett's metaplasia
81. p53 alterations in oesophageal cancer: Association with clinicopathological features, risk factors, and survival
82. p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations
83. Association of K-ras mutations with p16 methylation in human colon cancer
84. Activation of c-K-ras mutations in human gastrointestinal tumors
85. Ras mutation and expression of the rasregulated genes osteopontin and cathepsin L in human esophageal cancer
86. K-ras point mutations are rare events in premalignant forms of Barrett's oesophagus
87. K-ras codon 12 mutations in Barrett's oesophagus and adenocarcinomas of the oesophagus and oesophagogastric junction
88. Frequent c-myc amplification in high-grade dysplasia and adenocarcinoma in Barrett esophagus
89. Genomic alterations in malignant transformation of Barrett's esophagus
90. Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence
91. Flowcytometric and histological progression to malignancy in Barrett's esophagus: Prospective endoscopic surveillance of a cohort
92. Microsatellite instability and hMLH1/hMSH2 expression in Barrett esophagus-associated adenocarcinoma
93. Infrequent microsatellite instability in oesophageal cancers
94. Ubiquitous somatic alterations at microsatellite alleles occur infrequently in Barrett's-associated esophageal adenocarcinoma
95. Microsatellite instability in adenocarcinomas of the upper gastrointestinal tract. Relation to clinicopathological data and family history
96. Villin is a major protein of the microvillus cytoskeleton which binds both G and F actin in a calcium-dependent manner
97. Developmental regulation of villin gene expression in the epithelial cell lineages of mouse digestive and urogenital tracts
98. Identification of intestinal-type Barrett's metaplasia by using the intestine-specific protein villin and esophageal brush cytology
99. Abundant expression of the intestinal protein villin in Barrett's metaplasia and esophageal adenocarcinomas
100. Sucrase-isomaltase gene expression in Barrett's esophagus and adenocarcinoma
101. Intestinal differentiation and p53 gene alterations in Barrett's esophagus and esophageal adenocarcinoma
102. Mucin gene expression in Barrett's oesophagus: An in situ hybridisation and immunohistochemical study
103. Expression of MUC1 and MUC2 mucin gene products in Barrett's metaplasia, dysplasia and adenocarcinoma: An immunopathological study with clinical correlation
104. Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus
105. Isolation, characterization, and precise physical localization of human CDX1, a caudal-type homeobox gene
106. Isolation and characterization of the murine homeobox gene Cdx-1. Regulation of expression in intestinal epithelial cells
107. CDX1 protein expression in normal, metaplastic, and neoplastic human alimentary tract epithelium
108. Cytochromes P450 are expressed in proliferating cells in Barrett's metaplasia
109. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes
110. Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues
111. The immunocytochemical localisation and distribution of cytochrome P-450 in normal human hepatic and extrahepatic tissues with a monoclonal antibody to human cytochrome P-450
112. Characterization of cytochrome P450 expression in human oesophageal mucosa
113. Increased c-myb mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma
114. DNA methylation analysis of the promoter region of the human telomerase reverse transcriptase (hTERT) gene
115. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma
116. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence
117. Retinoic acid receptor-alpha messenger RNA expression is increased and retinoic acid receptor-gamma expression is decreased in Barrett's intestinal metaplasia, dysplasia, adenocarcinoma sequence
118. Evolution of neoplastic cell lineages in Barrett oesophagus